Európai Unió - magyar - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - legfeljebb három, a következő tisztított, inaktivált, láb -, illetve-száj betegség vírus törzsek: o1 manisa ≥ 6 pd50*; o1 bfs ≥ 6 pd50*; o tajvan 3/97 ≥ 6 pd50*; a22 iraki ≥ 6 pd50*; a24 cruzeiro ≥ 6 pd50*; pulyka 14/98 ≥ 6 pd50*; Ázsia 1 shamir ≥ 6 pd50*; szo2 szaúd-arábia ≥ 6 pd50*; * pd50 – 50% - a védő adag marha leírt ph eur. monográfia 0063. - immunológikumok - pigs; cattle; sheep - a szarvasmarhák, a juhok és a sertések 2 hetes aktív immunizálása a ragadós száj- és körömfájás ellen a klinikai tünetek csökkentése érdekében.

Európai Unió - magyar - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunológikumok a felidae, - macskák - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Európai Unió - magyar - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunológikumok a felidae, - macskák - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Európai Unió - magyar - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - sertés - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Európai Unió - magyar - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - a vakcinák - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Európai Unió - magyar - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - az a / vietnam / 1194/2004 (h5n1) törzs influenzavírus-felületi antigénjei (hemagglutinin és neuraminidáz) - influenza, human; immunization; disease outbreaks - a vakcinák - aktív immunizálás az influenza a vírus h5n1 altípusa ellen. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Európai Unió - magyar - EMA (European Medicines Agency)

zoetis belgium sa - inactivated bluetongue virus, serotype 1, strain btv-1/alg2006/01, inactivated bluetongue virus, serotype 8, strain btv-8/bel2006/02 - bluetongue virus, sheep, inactivated viral vaccines - juh - a juhok aktív immunizálása 1. 5 hónapos korban a kéknyelvbetegség vírus által okozott vírus megakadályozására, az 1. és a 8. szerotípusra. a védettség kezdete: 21 nappal az elsődleges vakcinázási rendszer befejezése után. a mentesség időtartama: 12 hónap.

Európai Unió - magyar - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - inaktivált, antigént tartalmazó influenza vírus: a / vietnam / 1194/2004 (h5n1), mint a használt törzs (nibrg-14) - influenza, human; immunization; disease outbreaks - a vakcinák - aktív immunizálás az influenza a vírus h5n1 altípusa ellen. ez a jelzés alapján immunogenitási adatok az egészséges személyek kortól 18 éves kezdődően alkalmazását követően, két adag oltóanyag készült a/vietnam/1194/2004 nibrg-14 (h5n1) (lásd 5. a prepandémiás influenza (h5n1) vakcina (split virion, inaktivált, adjuvánshoz kötött) glaxosmithkline biologicals 3. 75 µg kell alkalmazni hivatalos ajánlásoknak megfelelően.

Magyarország - magyar - NÉBIH (Nemzeti Élelmiszerlánc-biztonsági Hivatal)

alpha-vet Állatgyógyászati kft. - bovine respiratory syncytial virus, strain bio-24, inactivated, mannheimia haemolytica, serotype a1, strain dsm 5283, inactivated, bovine parainfluenza virus 3, strain bio-23, inactivated - szuszpenziós injekció - inactivated bovine parainfluenza virus vaccine + inactivated bovine re - szarvasmarha

Magyarország - magyar - NÉBIH (Nemzeti Élelmiszerlánc-biztonsági Hivatal)

alpha-vet Állatgyógyászati kft. - bovine respiratory syncytial virus, strain bio-24, inactivated, bovine viral diarrhoea virus, strain bio-25, inactivated, mannheimia haemolytica, serotype a1, strain dsm 5283, inactivated, bovine parainfluenza virus 3, strain bio-23, inactivated - szuszpenziós injekció - inactivated viral and inactivated bacterial vaccines - szarvasmarha